New Drugs
| Brand/Generic | Company | Description |
|---|---|---|
|
Abecma idecabtagene vicleucel |
Celgene | Intravenous T-cell immunotherapy for multiple myeloma. |
|
Abrilada adalimumab |
Pfizer | A biosimilar to Humira. |
|
Braftovi encorafenib |
Pfizer | A kinase inhibitor for unresectable or metastatic melanoma (used with binimetinib). |
|
Brukinsa zanubrutinib |
BeiGene | Oral Bruton tyrosine kinase inhibitor for Waldenström’s macroglobulinemia. |
|
Dojolvi triheptanoin |
Ultragenyx | Oral medium-chain triglyceride for long-chain fatty acid oxidation disorders. |
|
Enhertu trastuzumab deruxtecan |
AstraZeneca | A monoclonal antibody for unresectable/metastatic HER2-positive breast cancer. |
|
Evrysdi risdiplam |
Hoffmann-La Roche | An oral agent for spinal muscular atrophy. |
|
Foclivia pandemic influenza vaccine |
Seqirus | An H5N1 flu vaccine for influenza prevention in officially declared pandemic situations. |
|
Gavreto pralsetinib |
Hoffmann-La Roche | An oral kinase inhibitor for advanced/metastatic non-small cell lung cancer. |
|
Kesimpta ofatumumab |
Novartis | A monoclonal antibody for relapsing-remitting multiple sclerosis. |
|
Ledaga chlormethine |
Recordati Rare Diseases Canada | A topical alkylating agent for mycosis fungoides-type cutaneous T-cell lymphoma. |
|
Mektovi binimetinib |
Pfizer | A kinase inhibitor for unresectable or metastatic melanoma (used with encorafenib). |
|
Nextstellis estetrol/drospirenone |
Searchlight Pharma | A new combined oral contraceptive. |
|
Phesgo pertuzumab/trastuzumab |
Hoffmann-La Roche | Monoclonal antibody fixed-dose combo for early and metastatic breast cancer. |
|
Ponvory ponesimod |
Janssen | Oral sphingosine-1-phosphate receptor 1 modulator for relapsing remitting MS. |
|
Retevmo selpercatinib |
Loxo (US)/Lilly | Oral protein kinase inhibitor for advanced/metastatic NSCLC, thyroid cancer. |
|
Riabni rituximab |
Amgen | A new biosimilar to Rituxan. |
|
Sunosi solriamfetol |
Jazz Pharma | Oral dopamine/norepinenephrine reuptake inhibitor to improve wakefulness in narcolepsy/obstructive sleep apnea. |
|
Supemtek influenza vaccine |
Sanofi Pasteur | A quadrivalent vaccine for prevention of influenza in adults. |
|
Tecartus brexucabtagene autoleucel |
Gilead Sciences | An immunotherapy agent for relapsed or refractory mantle cell lymphoma. |
|
Tepmetko tepotinib |
EMD Serono | An oral protein kinase inhibitor for non-small cell lung cancer. |
|
Triferic Avnu ferric pyrophosphate citrate |
Rockwell Medical (US)/RMC Healthcare (CAN) | Intravenous iron replacement therapy to maintain hemoglobin in hemodialysis-dependent chronic kidney disease. |
|
Trikafta elexacaftor/tezacaftor/ ivacaftor |
Vertex | An oral CFTR corrector and potentiator for cystic fibrosis. |
|
Vistaseal fibrin sealant (human) |
Grifols (SA)/J&J Medical | A topical hemostatic to improve hemostasis during surgery. |
|
Vyepti eptinezumab |
Lundbeck | An injectable CGRP-binding antibody for migraine prevention in adults. |
|
Wakix pitolisant |
Endo (Ireland)/ Paladin | An oral H-3 receptor antagonist/inverse agonist for excessive daytime sleepiness/cataplexy in narcolepsy. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Arazlo tazarotene |
Bausch Health | New strength (0.045%) topical lotion for acne. |
|
Bryhali halobetasol |
Bausch Health | New high/super-high potency 0.01% topical steroid lotion for dermatoses and plaque psoriasis. |
|
Cequa cyclosporine |
Sun Pharma | New 0.09% ophthalmic solution for moderate/severe dry eye. |
|
Inprosub progesterone |
IBSA (Switz) | New subcutaneous formulation for in vitro fertilization treatment. |
|
Onureg azacitidine |
Celgene/BMSquibb | New oral formulation for maintenance therapy in adults with acute myeloid leukemia. |
|
Vyndamax tafamidis |
Pfizer | New higher-strength (61 mg) capsule formulation for cardiomyopathy. |
|
Vyxeos cytarabine/ daunorubicin |
Jazz Pharma | New combination antineoplastic liposomal formulation for certain types of acute myeloid leukemia. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Ruzurgi amifampridine |
Médunik Canada | No longer marketed in Canada as Notice of Compliance is invalid. Another formulation of amifampridine (Firdapse) will continue to be available. |